147 related articles for article (PubMed ID: 34362476)
1. [Clinical Significance of Truncated Mutant ΔJBP of TET2 Gene in Patients with Acute Myeloid Leukemia].
Yang YC; Xia T; Luo M; Guo WZ; Zhang LL; Chen XH; Xu ZF; Wang HW; Tan YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1011-1018. PubMed ID: 34362476
[TBL] [Abstract][Full Text] [Related]
2. [Gene Profile and Clinical Significance of Concomitant Mutations in CN-AML Patients with
Zhu J; Kang YF; Gao Y; Wang HW; Hao ZH; Wang HW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):335-341. PubMed ID: 38660833
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
Wang R; Gao X; Yu L
BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
[TBL] [Abstract][Full Text] [Related]
4. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
[TBL] [Abstract][Full Text] [Related]
5. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
6. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
[TBL] [Abstract][Full Text] [Related]
7. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
Grossmann V; Haferlach C; Nadarajah N; Fasan A; Weissmann S; Roller A; Eder C; Stopp E; Kern W; Haferlach T; Kohlmann A; Schnittger S
Br J Haematol; 2013 Jun; 161(5):649-658. PubMed ID: 23521373
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.
Liu WJ; Tan XH; Luo XP; Guo BP; Wei ZJ; Ke Q; He S; Cen H
Leuk Lymphoma; 2014 Dec; 55(12):2691-8. PubMed ID: 24524305
[TBL] [Abstract][Full Text] [Related]
9. Landscape of TET2 mutations in acute myeloid leukemia.
Weissmann S; Alpermann T; Grossmann V; Kowarsch A; Nadarajah N; Eder C; Dicker F; Fasan A; Haferlach C; Haferlach T; Kern W; Schnittger S; Kohlmann A
Leukemia; 2012 May; 26(5):934-42. PubMed ID: 22116554
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of the Effect of TET2 Mutation and SNP on Clinical Characteristics and Prognosis of AML Patients].
Li L; An LC; Chu XX; Liu XQ; Wang L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):453-459. PubMed ID: 32319378
[TBL] [Abstract][Full Text] [Related]
11. TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression.
Heyes E; Wilhelmson AS; Wenzel A; Manhart G; Eder T; Schuster MB; Rzepa E; Pundhir S; D'Altri T; Frank AK; Gentil C; Woessmann J; Schoof EM; Meggendorfer M; Schwaller J; Haferlach T; Grebien F; Porse BT
Nat Commun; 2023 Oct; 14(1):6185. PubMed ID: 37794021
[TBL] [Abstract][Full Text] [Related]
12. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.
Cher CY; Leung GM; Au CH; Chan TL; Ma ES; Sim JP; Gill H; Lie AK; Liang R; Wong KF; Siu LL; Tsui CS; So CC; Wong HW; Yip SF; Lee HK; Liu HS; Lau JS; Luk TH; Lau CK; Lin SY; Kwong YL; Leung AY
Blood Cancer J; 2016 Jul; 6(7):e442. PubMed ID: 27391574
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique.
Wang RQ; Chen CJ; Jing Y; Qin JY; Li Y; Chen GF; Zhou W; Li YH; Wang J; Li DW; Zhao HM; Wang BH; Wang LL; Wang H; Wang MZ; Gao XN; Yu L
Cancer Med; 2020 Nov; 9(22):8457-8467. PubMed ID: 32970934
[TBL] [Abstract][Full Text] [Related]
14. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
16. Companion gene mutations and their clinical significance in AML with double or single mutant CEBPA.
He J; Liu J; Shen H; Wang Z; Cao L; Wu P; Chao H; Lu X; Jia Z; Chen M; Cai X
Int J Hematol; 2022 Jul; 116(1):71-80. PubMed ID: 35314954
[TBL] [Abstract][Full Text] [Related]
17. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
[No Abstract] [Full Text] [Related]
18. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
[TBL] [Abstract][Full Text] [Related]
19. TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public database.
Pan X; Chang Y; Ruan G; Zhou S; Jiang H; Jiang Q; Huang X; Zhao XS
Clin Exp Med; 2024 Feb; 24(1):35. PubMed ID: 38349460
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic significance of different IDH mutations and accompanying gene mutations in patients with acute myeloid leukemia].
Wu RY; Xie XS; Wei Y; Jang ZX; Chen DD; Sun H; Wan DM; Liu YF; Sun L
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):39-44. PubMed ID: 33677867
[No Abstract] [Full Text] [Related]
[Next] [New Search]
